By Matt Grossman


Immunome Inc. has submitted an investigational new drug application to the Food and Drug Administration for a three-antibody cocktail intended to treat Covid-19.

The cocktail, called IMM-BCP-01, has shown in lab studies that it neutralizes the virus and reduces viral load in the lungs of infected hamsters, Immunome said. In those studies the cocktail was effective against Covid-19 variants, including the Delta variant.

Outside of Immunome, scientists have begun researching whether the newly discovered Omicron variant has become less susceptible to existing antibody-based treatments.

When the FDA accepts the application, Immunome will work to begin a study of IMM-BCP-01 in infected patients, the Pennsylvania-based company said.


Write to Matt Grossman at


(END) Dow Jones Newswires

November 29, 2021 07:31 ET (12:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.